Riskpilot← Back to searchSign inGet full accessALFIMED AS
ASActiveOrg 892142262Olav Brunborgs Vei 6, 1396 BillingstadWholesale of pharmaceutical and medical goods · NACE 4646Est. 20087 employees
Revenue 2025
NOK 35,1M
+13% vs 2024
EBITDA margin
24.3%
+48% vs 2024
Equity ratio
27.4%
Financial strength
Net profit 2025
NOK 6,6M
+58% vs 2024
| Revenue | NOK 35,1M | +13% |
| EBITDA | NOK 8,5M | +48% |
| Net profit | NOK 6,6M | +58% |
| Total assets | NOK 15,5M | +31% |
| Equity | NOK 4,2M | +15% |
| Employees | 7 | — |
Legal name
ALFIMED AS
Org number
892142262
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. januar 2008
Share capital
NOK 100 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Import og distribusjon av produkter til bruk innen helse og sykehusvesen, fortrinnsvis ortopediske produkter.
Address
Olav Brunborgs Vei 6, 1396 Billingstad
Phone
+4797106838
Email
info@alfimed.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 19 442 | 18 502 | 21 869 | 31 195 | 35 133 |
| Staff expenses | −3 572 | −4 001 | −4 038 | −4 974 | −4 739 |
| EBITDA | 7 300 | 4 641 | 4 404 | 5 784 | 8 537 |
| Depreciation & amort. | −47 | −65 | −65 | −44 | −88 |
| EBIT | 7 252 | 4 576 | 4 338 | 5 740 | 8 449 |
| Net financials | −1 | −2 | −862 | −302 | −4 |
| Profit before tax | 7 252 | 4 574 | 3 477 | 5 437 | 8 446 |
| Tax | 1 607 | 1 055 | 990 | 1 296 | 1 887 |
| Net profit | 5 645 | 3 519 | 2 486 | 4 141 | 6 559 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 11 081 | 9 731 | 9 774 | 11 862 | 15 482 |
| Equity | 2 836 | 3 655 | 3 141 | 3 682 | 4 241 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8 245 | 6 076 | 6 633 | 8 179 | 11 241 |
| Total debt | 8 245 | 6 076 | 6 633 | 8 179 | 11 241 |
EBITDA margin
24.3%
This company
15.8%
Market median
+54% vs market
20212025
Equity ratio
27.4%
This company
38.2%
Market median
-28% vs market
20212025
Return on equity
154.6%
This company
18.4%
Market median
+740% vs market
20212025
Net profit margin
18.7%
This company
8.1%
Market median
+131% vs market
20212025
Asset turnover
2.27×
This company
1.12×
Market median
+103% vs market
20212025
Debt / equity
2.65×
This company
0.62×
Market median
-327% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LE Deputy Member | Deputy Member | 2013 |
GA Chief Executive Officer | Chief Executive Officer | 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Allard Support For Better Life Ab | Company | 50% | 50% | 2024 |
| Individual | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ALFIMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Elisabeth Lindgren | Deputy Member | 0 companies |
| Geir Aarø Finnerud | Chief Executive Officer | 0 companies |
| Jens Peter Allard | Chairman | 0 companies |